Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections

ClinicalTrials.gov ID: NCT00643292

Public ClinicalTrials.gov record NCT00643292. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Amoxicillin/Clavulanate Potassium (Augmentin ES-600 Trademark) for the Treatment of Acute Otitis Media in Children Undergoing Diagnostic Tympanocentesis

Study identification

NCT ID
NCT00643292
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
902 participants

Conditions and interventions

Interventions

  • amoxicillin/clavulanate postassium (Augmentin ES-600) Drug
  • azithromycin SR Drug

Drug

Eligibility (public fields only)

Age range
3 Months to 48 Months
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2002
Primary completion
Not listed
Completion
Apr 30, 2004
Last update posted
May 16, 2011

2003 – 2004

United States locations

U.S. sites
23
U.S. states
9
U.S. cities
21
Facility City State ZIP Site status
Pfizer Investigational Site Jonesboro Arkansas 72401
Pfizer Investigational Site Little Rock Arkansas 72202
Pfizer Investigational Site Bellflower California 90706
Pfizer Investigational Site Fountain Valley California 92708
Pfizer Investigational Site Fresno California 93710
Pfizer Investigational Site Fresno California 93720
Pfizer Investigational Site Huntington Beach California 92647
Pfizer Investigational Site Newhall California 91321
Pfizer Investigational Site Orange California 92868
Pfizer Investigational Site Paramount California 90723
Pfizer Investigational Site Pico Rivera California 90660
Pfizer Investigational Site Bridgeport Connecticut 06606
Pfizer Investigational Site Hartford Connecticut 06106
Pfizer Investigational Site Chicago Illinois 60625
Pfizer Investigational Site Chicago Illinois 60630
Pfizer Investigational Site Evanston Illinois 60202
Pfizer Investigational Site Bardstown Kentucky 40004
Pfizer Investigational Site Springfield Kentucky 40069
Pfizer Investigational Site Pittsburgh Pennsylvania 15213
Pfizer Investigational Site Dallas Texas 75234
Pfizer Investigational Site Payson Utah 84651
Pfizer Investigational Site Springville Utah 84663
Pfizer Investigational Site Vienna Virginia 22180

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00643292, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 16, 2011 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00643292 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →